Brief: Bicycle Therapeutics Announces Interim BT5528 Phase I Trial Results, Prelim Results From BT8009 Phase I Clinical Trial

Bicycle Therapeutics

07/10/2021 17:59

Oct 7 (Reuters) - Bicycle Therapeutics  BCYC.O :
    * BICYCLE THERAPEUTICS ANNOUNCES INTERIM BT5528 PHASE I
CLINICAL
TRIAL RESULTS AND PRELIMINARY RESULTS FROM ONGOING BT8009 PHASE
I CLINICAL TRIAL
    * BICYCLE THERAPEUTICS PLC - IN ONGOING BT8009 PHASE I TRIAL
IN
MONOTHERAPY COHORTS, 4 OUT OF 11 UROTHELIAL PATIENTS HAD PARTIAL
RESPONSES
    * BICYCLE THERAPEUTICS PLC - BT5528 PHASE I ANTI-TUMOR
ACTIVITY
OBSERVED IN LATE LINE PATIENTS
    * BICYCLE THERAPEUTICS PLC - A RECOMMENDED BT5528 PHASE II
DOSE
(RP2D) RANGE HAS BEEN ESTABLISHED ; EXPANSION COHORTS EXPECTED
TO INITIATE IN 2022
    * BICYCLE THERAPEUTICS PLC - LOOK FORWARD TO PROVIDING
ADDITIONAL
CLINICAL DATA ON BT5528 AND BT8009 NEXT YEAR
    * BICYCLE THERAPEUTICS PLC - INITIATING OUR PHASE I/II STUDY
FOR
BT7480 LATER THIS YEAR
    * BICYCLE THERAPEUTICS PLC - BT8009 PHASE I DOSE ESCALATION
REMAINS ONGOING, WITH NO DOSE LIMITING TOXICITIES (DLTS) YET
OBSERVED
    * BICYCLE THERAPEUTICS PLC - BT8009 ENROLLMENT ONGOING

Source text for Eikon:  urn:newsml:reuters.com:*:nBwbf6Bjha
Further company coverage:  BCYC.O 

 ((Reuters.Briefs@thomsonreuters.com;))